Virtu Financial’s Citius Pharmaceuticals CTXR Stock Holding History

Virtu Financial’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,016	Closed	-$50K	–	1632
2024 Q3	$50K	Buy	+4,016	New	+$67.6K	﹤0.01%	1012
2024 Q1	–	Sell	-2,059	Closed	-$39K	–	1526
2023 Q4	$39K	Buy	+2,059	New	+$39K	﹤0.01%	1214
2023 Q3	–	Sell	-954	Closed	-$29K	–	1414
2023 Q2	$29K	Buy	+954	New	+$31.4K	﹤0.01%	1206
2023 Q1	–	Sell	-1,560	Closed	-$31K	–	1615
2022 Q4	$31K	Buy	+1,560	New	+$42.6K	﹤0.01%	1173
2022 Q3	–	Sell	-3,256	Closed	-$75K	–	1810
2022 Q2	$75K	Buy	+3,256	New	+$89.3K	0.01%	1007
2021 Q3	–	Sell	-789	Closed	-$69K	–	1588
2021 Q2	$69K	Buy	+789	New	+$47.4K	0.01%	1278
2021 Q1	–	Sell	-5,907	Closed	-$151K	–	1664
2020 Q4	$151K	Buy	5,907 +1,338	+29%	+$34.9K	0.02%	944
2020 Q3	$119K	Buy	4,569 +897	+24%	+$25.3K	0.02%	691
2020 Q2	$104K	Buy	+3,672	New	+$80.3K	0.01%	871
2019 Q4	–	Sell	-661	Closed	-$13K	–	1503
2019 Q3	$13K	Buy	+661	New	+$17.4K	﹤0.01%	1327

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Virtu Financial's CTXR Position: Q4 2024 in Review

Virtu Financial sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 4,016 shares — an estimated $50K sold.

Virtu Financial first reported a position in CTXR in Q3 2019 and held it in 10 quarters. The position peaked at $151K in Q4 2020. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

Virtu Financial reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Virtu Financial sold 4,016 Citius Pharmaceuticals shares in Q4 2024, an estimated $50K.
Virtu Financial first reported a position in Citius Pharmaceuticals in Q3 2019 and held it in 10 quarters.
Virtu Financial's Citius Pharmaceuticals position peaked at $151K in Q4 2020.
30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.